138 related articles for article (PubMed ID: 22876881)
1. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.
Ellard K; Sunose M; Bell K; Ramsden N; Bergamini G; Neubauer G
Bioorg Med Chem Lett; 2012 Jul; 22(14):4546-9. PubMed ID: 22738635
[TBL] [Abstract][Full Text] [Related]
3. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
Murray JM; Sweeney ZK; Chan BK; Balazs M; Bradley E; Castanedo G; Chabot C; Chantry D; Flagella M; Goldstein DM; Kondru R; Lesnick J; Li J; Lucas MC; Nonomiya J; Pang J; Price S; Salphati L; Safina B; Savy PP; Seward EM; Ultsch M; Sutherlin DP
J Med Chem; 2012 Sep; 55(17):7686-95. PubMed ID: 22877085
[TBL] [Abstract][Full Text] [Related]
4. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
[TBL] [Abstract][Full Text] [Related]
5. Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.
Bhide RS; Neels J; Qin LY; Ruan Z; Stachura S; Weigelt C; Sack JS; Stefanski K; Gu X; Xie JH; Goldstine CB; Skala S; Pedicord DL; Ruepp S; Dhar TG; Carter PH; Salter-Cid LM; Poss MA; Davies P
Bioorg Med Chem Lett; 2016 Sep; 26(17):4256-60. PubMed ID: 27476421
[TBL] [Abstract][Full Text] [Related]
6. Fragment based discovery of a novel and selective PI3 kinase inhibitor.
Hughes SJ; Millan DS; Kilty IC; Lewthwaite RA; Mathias JP; O'Reilly MA; Pannifer A; Phelan A; Stühmeier F; Baldock DA; Brown DG
Bioorg Med Chem Lett; 2011 Nov; 21(21):6586-90. PubMed ID: 21925880
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.
Giordanetto F; Barlaam B; Berglund S; Edman K; Karlsson O; Lindberg J; Nylander S; Inghardt T
Bioorg Med Chem Lett; 2014 Aug; 24(16):3936-43. PubMed ID: 25042253
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
[TBL] [Abstract][Full Text] [Related]
9. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y
Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Giordanetto F; Green S; Inghardt T; Hennequin L; Hancox U; Lambert-van der Brempt C; Morgentin R; Pass S; Plé P; Saleh T; Ward L
Bioorg Med Chem Lett; 2014 Aug; 24(16):3928-35. PubMed ID: 24992874
[TBL] [Abstract][Full Text] [Related]
11. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.
Park H; Lee S; Hong S
Bioorg Med Chem Lett; 2012 Aug; 22(15):4946-50. PubMed ID: 22771009
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.
Shin Y; Suchomel J; Cardozo M; Duquette J; He X; Henne K; Hu YL; Kelly RC; McCarter J; McGee LR; Medina JC; Metz D; San Miguel T; Mohn D; Tran T; Vissinga C; Wong S; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang X; Cushing TD
J Med Chem; 2016 Jan; 59(1):431-47. PubMed ID: 26652588
[TBL] [Abstract][Full Text] [Related]
15. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
[TBL] [Abstract][Full Text] [Related]
16. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Sunose M; Bell K; Ellard K; Bergamini G; Neubauer G; Werner T; Ramsden N
Bioorg Med Chem Lett; 2012 Jul; 22(14):4613-8. PubMed ID: 22726925
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.
Hoegenauer K; Soldermann N; Hebach C; Hollingworth GJ; Lewis I; von Matt A; Smith AB; Wolf RM; Wilcken R; Haasen D; Burkhart C; Zécri F
Bioorg Med Chem Lett; 2016 Dec; 26(23):5657-5662. PubMed ID: 27816514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]